We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Theracryf Plc | LSE:TCF | London | Ordinary Share | GB00BSVYN304 | ORD 0.25P |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| -0.05 | -18.18% | 0.225 | 6,776,887 | 09:22:33 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 0.20 | 0.25 | 0.275 | 0.225 | 0.275 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 396k | -3.14M | -0.0073 | -0.30 | 1.18M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:10:04 | O | 333,333 | 0.24 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 04/3/2025 | 12:00 | UK RNS | Theracryf PLC Director/PDMR Shareholding |
| 24/2/2025 | 16:31 | UK RNS | Theracryf PLC Holding(s) in Company |
| 19/2/2025 | 11:09 | ALNC |  *TheraCryf calls March 7 GM for shareholders to approve equity raise |
| 19/2/2025 | 11:04 | UK RNS | Theracryf PLC £4.25m Placing and Subscription, Notice of GM |
| 19/2/2025 | 10:54 | UK RNS | Theracryf PLC Appointment of Dr Alastair Smith as Chair |
| 28/11/2024 | 14:25 | ALNC | TheraCryf narrows loss, advances drug programmes after acquisition |
| 28/11/2024 | 07:00 | UK RNS | Theracryf PLC Half-year Report |
| 27/11/2024 | 12:16 | ALNC | TheraCryf gets European patent for drug acquired from new subsidiary |
| 27/11/2024 | 07:00 | UK RNS | Theracryf PLC European Patent Office award decision |
| 15/11/2024 | 10:58 | UK RNS | Theracryf PLC Holding(s) in Company |
Theracryf (TCF) Share Charts1 Year Theracryf Chart |
|
1 Month Theracryf Chart |
Intraday Theracryf Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 04/3/2025 | 14:03 | Theracryf the new Evgen onwards and upwards | 253 |
| 28/11/2024 | 08:00 | ENJOY turning a WRECK into STAR RUNNER? | 40 |
| 29/9/2017 | 14:06 | Terra Catalyst Fund | 114 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 2025-03-04 16:10:05 | 0.24 | 333,333 | 800.00 | O |
| 2025-03-04 15:53:18 | 0.23 | 1,000,000 | 2,300.00 | O |
| 2025-03-04 15:07:53 | 0.23 | 19,845 | 46.44 | O |
| 2025-03-04 14:25:10 | 0.23 | 40,192 | 94.05 | O |
| 2025-03-04 14:24:28 | 0.23 | 200,000 | 467.00 | O |
| Top Posts |
|---|
Posted at 04/3/2025 08:20 by Theracryf Daily Update Theracryf Plc is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker TCF. The last closing price for Theracryf was 0.28p.Theracryf currently has 429,622,422 shares in issue. The market capitalisation of Theracryf is £945,169. Theracryf has a price to earnings ratio (PE ratio) of -0.30. This morning TCF shares opened at 0.28p |
Posted at 28/1/2025 11:07 by dave4545 0.55p was a nice price now eh |
Posted at 15/1/2025 13:32 by xxproinvestorxx Share price continues to make gains. Looks very good, when we gets Stalicla news we should fly |
Posted at 07/1/2025 22:45 by thiopia Comparing TCF and PYC for upside potentialTCF - Theracryf PYC - Physiomics TCF - share price 0.75p Mkt Cap £3m PYC - share price 0.75p Mkt Cap £1.5m 52 week high as of (Jan 2025) TCF - 1.85p PYC - 1.85p Charting w.r.t 50/200 day Moving Averages TCF is currently above the 50 and 200 day Moving Averages PYC is currently in between narrowing 50 and 200 Moving Averages Potential Catalysts ? PYC - consulting contracts ? software/IP development with partners such as DoseMeRX / Beyond Blood Diagnostics ? Government grants to run NHS trials ? TCF - has an existing $160m deal with Stalicla where a $0.5m milestone payment has been due/overdue for 12 months and another $5m milestone could be imminent for their Autism candidate. TCF claim to be in amicable discussions with Stalicla to resolve this issue. $0.5m would be very meaningful to a £3m company. $5m utterly transformational. |
Posted at 03/1/2025 13:15 by dave4545 None of those buys are mine but a few people quickly got stuck in and price has shot up to full 0.65p offerTraders or somebody knows something ? |
Posted at 14/11/2024 15:36 by tomboyb TCF had £2million pounds left at the end of March -They will need to raise very soon - |
Posted at 06/11/2024 09:01 by clocktower Well the Trump supporters and the markets seem euphorice this morning, and you never know TCF might soon benefit from the excitment in the market, and small pharma stocks may well become attractive once again.Only takes a bit of good news or a new deal and these sort of stocks fly, and become attractive because of the tax advantages in the UK. |
Posted at 01/11/2024 11:58 by clocktower I am not familiar with the UK tax regime but reading about the capital gains tax changes, would I be correct that some ISA investors might have been selling up across the board to ensure they were not going to be hit by the recent budget?Selling their whole portfolio even if it included duffers like this, which would be responsible in part for the very low share price. I would appreciate it is someone could enlighten me on the subject. |
Posted at 31/10/2024 14:27 by xxproinvestorxx Once Stalicla complete their series C raise, where they are targeting $60-75m, I have no doubt that we'll receive news on them paying us the money owed and their plans to advance STP2 into Phase 2. After all, STP2 has been validated by them as the primary candidate to treat Phenotype 2 ASD, which has a total addressable market in excess of $2B. Clock - Stalicla don't currently have the funds to buy out Theracryf (maybe after series C raise?), and I highly doubt 1p would be accepted by most shareholders, nor would I expect the bod to put forward such a lowball offer to shareholders.The share price is where it is due to several factors and I completely disagree regarding your comments on the share price being where it is due to Stalicla having no intention of ever paying the money for P1 trial completion. The uncertainty is why we are where we are, combined with the wider aim and small biotech environment. |
Posted at 12/6/2024 13:46 by clocktower Great volume once again, it seems to be building up a head of steam before tomorrows R & D update, which based on the buying of late is likely to send the share price a lot higher, as it is nodoubt very positive, as it is unlikely we would have seen the slow increase in the share price lately, if it were not. |
Posted at 04/6/2024 19:03 by terrydevlin1 Good luck Mark and CT. Whilst the Stalicla deal is still live I can’t see how this can go down much lower. But that deal looks to be on the rocks IMO. The fact TCF no longer mentioned up to $5.5m expected this year in the full results and Stalicla also removed from their website that this would go into phase 2 in 2024, it doesn’t look good. If the deal collapses this share price will be 0.1p and it’s game over. I question where is the money going to come from to bankroll this company? TCF needs between £3m and £4m a year which is enormous sums of money.I’ve been doing alright recently on the virtual dogs at the bookies, I’d rather stick a grand on a virtual dog than this dog of a share. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
